Blood Cancer Journal (Nov 2023)
Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study
- Dan Xu,
- Ying Yang,
- Zhao Yin,
- Sanfang Tu,
- Danian Nie,
- Yiqing Li,
- Zhenqian Huang,
- Qixin Sun,
- Changfen Huang,
- Xiaqi Nie,
- Zurong Yao,
- Pengcheng Shi,
- Yu Zhang,
- Xuejie Jiang,
- Qifa Liu,
- Guopan Yu
Affiliations
- Dan Xu
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Ying Yang
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Zhao Yin
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Sanfang Tu
- Department of Hematology, Zhujiang Hospital, Southern Medical University
- Danian Nie
- Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
- Yiqing Li
- Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
- Zhenqian Huang
- Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University
- Qixin Sun
- Department of Hematology, Guangzhou First People’s Hospital
- Changfen Huang
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Xiaqi Nie
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Zurong Yao
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Pengcheng Shi
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Yu Zhang
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Xuejie Jiang
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Qifa Liu
- Department of Hematology, Nanfang Hospital, Southern Medical University
- Guopan Yu
- Department of Hematology, Nanfang Hospital, Southern Medical University
- DOI
- https://doi.org/10.1038/s41408-023-00941-4
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 7
Abstract
No abstracts available.
